»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD) Ä¡·áÁ¦ ½ÃÀåÀº 2024-2029³â¿¡ 78¾ï 4,100¸¸ ´Þ·¯ Áõ°¡Çϰí, ¿¹Ãø±â°£ Áß CAGR·Î 6.4%ÀÇ ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù.
¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD) Ä¡·áÁ¦ ½ÃÀåÀÇ ÀüüÀûÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð¡¤¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¸¦ ´Ù·é º¥´õ ºÐ¼® µîÀ» °ÔÀçÇϰí ÀÖ½À´Ï´Ù.
ÇöÀçÀÇ ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ¼ºÀå¿äÀÎ, Àüü ½ÃÀå ȯ°æ¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù.
½ÃÀåÀº COPD À¯º´·ü Áõ°¡, °·ÂÇÑ ÆÄÀÌÇÁ¶óÀΰú ½Å¾à ½ÂÀÎ, º¹ÇÕÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§
±âÁØ¿¬µµ
2025
Á¾·á¿¬µµ
2029
¿¹Ãø ±â°£
2025-2029
¼ºÀå ¸ð¸àÅÒ
°¡¼Ó
Àü³â´ëºñ
5.8%
CAGR
6.4%
Áõ°¡¾×
78¾ï 4,100¸¸ ´Þ·¯
º» Á¶»ç´Â ¾÷°è ÁÖ¿ä Âü¿©ÀÚµéÀÇ ÀǰßÀ» Æ÷ÇÔÇÏ¿© 1Â÷ Á¤º¸¿Í 2Â÷ Á¤º¸¸¦ °´°üÀûÀ¸·Î Á¶ÇÕÇÏ¿© ½Ç½ÃµÇ¾ú½À´Ï´Ù.
ÀÌ º¸°í¼¿¡´Â ÁÖ¿ä ±â¾÷ ºÐ¼®°ú ÇÔ²² Á¾ÇÕÀûÀÎ ½ÃÀå ±Ô¸ð µ¥ÀÌÅÍ, Áö¿ªº° ºÐ¼®¿¡ µû¸¥ ºÎ¹®, °ø±Þ¾÷ü ÇöȲÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.
º¸°í¼¿¡´Â °ú°Å µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅͰ¡ ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼´Â ÇâÈÄ ¼ö³â°£ ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD) Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª·Î Ä¡·áÀû Á¢±Ù¹ýÀÇ ¿¬±¸ È®´ë¸¦ ²Å°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ ¾à¹°Àü´Þ ÀåÄ¡ÀÇ ¹ßÀü°ú ÈíÀÔ ¿ä¹ýÀÇ È®´ë´Â ½ÃÀåÀÇ Å« ¼ö¿ä·Î À̾îÁú °ÍÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå °³¿ä
Á¦2Àå Technavio ºÐ¼®
°¡°Ý¡¤¼ö¸íÁֱ⡤°í°´ ±¸ÀÔ ¹Ù½ºÄÏ¡¤Ã¤Å÷ü¡¤±¸ÀÔ ±âÁØÀÇ ºÐ¼®
ÀÎDzÀÇ Á߿伺°ú Â÷º°ÈÀÇ ¿äÀÎ
È¥¶õÀÇ ¿äÀÎ
ÃËÁø¿äÀΰú °úÁ¦ÀÇ ¿µÇâ
Á¦3Àå ½ÃÀå ±¸µµ
½ÃÀå ¿¡ÄڽýºÅÛ
½ÃÀåÀÇ Æ¯Â¡
¹ë·ùüÀÎ ºÐ¼®
Á¦4Àå ½ÃÀå ±Ô¸ð
½ÃÀåÀÇ Á¤ÀÇ
½ÃÀå ºÎ¹® ºÐ¼®
½ÃÀå ±Ô¸ð 2024
½ÃÀå Àü¸Á 2024-2029
Á¦5Àå ½ÃÀå ±Ô¸ð ½ÇÀû
¼¼°èÀÇ ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD) Ä¡·áÁ¦ ½ÃÀå 2019-2023
Á¦Ç°º° ºÎ¹® ºÐ¼® 2019-2023
À¯Åë ä³Îº° ºÎ¹® ºÐ¼® 2019-2023
Åõ¿© °æ·Îº° ºÎ¹® ºÐ¼® 2019-2023
Áúȯ À¯Çüº° ºÎ¹® ºÐ¼® 2019-2023
Áö¿ªº° ºÎ¹® ºÐ¼® 2019-2023
±¹°¡º° ºÎ¹® ºÐ¼® 2019-2023
Á¦6Àå Á¤¼º ºÐ¼®
AIÀÇ ¿µÇâ : ¼¼°èÀÇ ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD) Ä¡·áÁ¦ ½ÃÀå
Á¦7Àå Five Forces ºÐ¼®
Five Forces ¿ä¾à
¹ÙÀ̾îÀÇ ±³¼··Â
°ø±Þ ±â¾÷ÀÇ ±³¼··Â
½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
´ëüǰÀÇ À§Çù
°æÀïÀÇ À§Çù
½ÃÀå ÇöȲ
Á¦8Àå ½ÃÀå ¼¼ºÐÈ : Á¦Ç°º°
½ÃÀå ºÎ¹®
ºñ±³ : Á¦Ç°º°
º´¿ë¿ä¹ý : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
´Üµ¶¿ä¹ý : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
½ÃÀå ±âȸ : Á¦Ç°º°
Á¦9Àå ½ÃÀå ¼¼ºÐÈ : À¯Åë ä³Îº°
½ÃÀå ºÎ¹®
ºñ±³ : À¯Åë ä³Îº°
º´¿ø ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
¼Ò¸Å ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
¿Â¶óÀÎ ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
½ÃÀå ±âȸ : À¯Åë ä³Îº°
Á¦10Àå ½ÃÀå ¼¼ºÐÈ : Åõ¿© °æ·Îº°
½ÃÀå ºÎ¹®
ºñ±³ : Åõ¿© °æ·Îº°
ÈíÀÔ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
°æ±¸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
ÁÖ»ç : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
½ÃÀå ±âȸ : Åõ¿© °æ·Îº°
Á¦11Àå ½ÃÀå ¼¼ºÐÈ : Áúȯ À¯Çüº°
½ÃÀå ºÎ¹®
ºñ±³ : Áúȯ À¯Çüº°
¸¸¼º ±â°üÁö¿° : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
Æó±âÁ¾ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
½ÃÀå ±âȸ : Áúȯ À¯Çüº°
Á¦12Àå °í°´ »óȲ
Á¦13Àå Áö¿ªº° »óȲ
Áö¿ªº° ¼¼ºÐÈ
Áö¿ªº° ºñ±³
ºÏ¹Ì : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
À¯·´ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
¾Æ½Ã¾Æ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
¼¼°èÀÇ ±âŸ Áö¿ª : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
¹Ì±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
ij³ª´Ù : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
µ¶ÀÏ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
Áß±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
ÇÁ¶û½º : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
¿µ±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
ÀϺ» : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
½ºÆäÀÎ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
ºê¶óÁú : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
³×´ú¶õµå : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029
½ÃÀå ±âȸ : Áö¿ª »óȲº°
Á¦14Àå ÃËÁø¿äÀΡ¤°úÁ¦¡¤±âȸ¡¤¾ïÁ¦¿äÀÎ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
ÃËÁø¿äÀΰú °úÁ¦ÀÇ ¿µÇâ
½ÃÀåÀÇ ±âȸ¡¤¾ïÁ¦¿äÀÎ
Á¦15Àå °æÀï ±¸µµ
°³¿ä
°æÀï ±¸µµ
È¥¶õ »óȲ
¾÷°èÀÇ ¸®½ºÅ©
Á¦16Àå °æÀï ºÐ¼®
±â¾÷ °³¿ä
±â¾÷ ¼øÀ§ Áö¼ö
±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Cadila Pharmaceuticals Ltd.
Cipla Inc.
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
Innoviva Inc.
Lupin Ltd.
Merck and Co. Inc.
Novartis AG
SHIONOGI Co. Ltd.
Sumitomo Pharma Co. Ltd.
Teva Pharmaceutical Industries Ltd.
Theravance Biopharma Inc.
Viatris Inc.
Á¦17Àå ºÎ·Ï
KSA
The chronic obstructive pulmonary disease drugs market is forecasted to grow by USD 7,841 mn during 2024-2029, accelerating at a CAGR of 6.4% during the forecast period. The report on the chronic obstructive pulmonary disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of copd, strong pipeline and new drug approvals, and growing demand for fixed-dose combinations.
Market Scope
Base Year 2025
End Year 2029
Series Year 2025-2029
Growth Momentum Accelerate
YOY 2025 5.8%
CAGR 6.4%
Incremental Value $7,841 mn
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
Technavio's chronic obstructive pulmonary disease drugs market is segmented as below:
By Product
Combination therapy
Monotherapy
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Route Of Administration
Inhalation
Oral
Injectable
By Disease Type
Chronic bronchitis
Emphysema
By Geographical Landscape
North America
Europe
Asia
Rest of World (ROW)
This study identifies the expanding research in curative approaches as one of the prime reasons driving the chronic obstructive pulmonary disease drugs market growth during the next few years. Also, advances in drug delivery devices and expansion of inhalation therapies will lead to sizable demand in the market.
The report on the chronic obstructive pulmonary disease drugs market covers the following areas:
Chronic Obstructive Pulmonary Disease Drugs Market sizing
Chronic Obstructive Pulmonary Disease Drugs Market forecast
Chronic Obstructive Pulmonary Disease Drugs Market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic obstructive pulmonary disease drugs market vendors that include AstraZeneca Plc, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., CHIESI Farmaceutici SpA, Cipla Inc., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Innoviva Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, SHIONOGI Co. Ltd., Sumitomo Pharma Co. Ltd., Teva Pharmaceutical Industries Ltd., Theravance Biopharma Inc., Viatris Inc., and Phillips Medisize. Also, the chronic obstructive pulmonary disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
1.1 Market overview
Executive Summary - Chart on Market Overview
Executive Summary - Data Table on Market Overview
Executive Summary - Chart on Global Market Characteristics
Executive Summary - Chart on Market By Geographical Landscape
Executive Summary - Chart on Market Segmentation by Product
Executive Summary - Chart on Market Segmentation by Distribution Channel
Executive Summary - Chart on Market Segmentation by Route of Administration
Executive Summary - Chart on Market Segmentation by Disease Type
Executive Summary - Chart on Incremental Growth
Executive Summary - Data Table on Incremental Growth
Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
Overview on criticality of inputs and factors of differentiation
2.3 Factors of disruption
Overview on factors of disruption
2.4 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
3.1 Market ecosystem
Parent Market
Data Table on - Parent Market
3.2 Market characteristics
Market characteristics analysis
3.3 Value chain analysis
4 Market Sizing
4.1 Market definition
Offerings of companies included in the market definition
4.2 Market segment analysis
4.3 Market size 2024
4.4 Market outlook: Forecast for 2024-2029
Chart on Global - Market size and forecast 2024-2029 ($ million)
Data Table on Global - Market size and forecast 2024-2029 ($ million)
Chart on Global Market: Year-over-year growth 2024-2029 (%)
Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
5.1 Global Chronic Obstructive Pulmonary Disease Drugs Market 2019 - 2023
Historic Market Size - Data Table on Global Chronic Obstructive Pulmonary Disease Drugs Market 2019 - 2023 ($ million)
5.2 Product segment analysis 2019 - 2023
Historic Market Size - Product Segment 2019 - 2023 ($ million)
5.3 Distribution Channel segment analysis 2019 - 2023
Historic Market Size - Distribution Channel Segment 2019 - 2023 ($ million)
5.4 Route of Administration segment analysis 2019 - 2023
Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million)
5.5 Disease Type segment analysis 2019 - 2023
Historic Market Size - Disease Type Segment 2019 - 2023 ($ million)
5.6 Geography segment analysis 2019 - 2023
Historic Market Size - Geography Segment 2019 - 2023 ($ million)
5.7 Country segment analysis 2019 - 2023
Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Qualitative Analysis
6.1 The AI impact on Global Chronic Obstructive Pulmonary Disease Drugs Market
7 Five Forces Analysis
7.1 Five forces summary
Five forces analysis - Comparison between 2024 and 2029
7.2 Bargaining power of buyers
Bargaining power of buyers - Impact of key factors 2024 and 2029
7.3 Bargaining power of suppliers
Bargaining power of suppliers - Impact of key factors in 2024 and 2029
7.4 Threat of new entrants
Threat of new entrants - Impact of key factors in 2024 and 2029
7.5 Threat of substitutes
Threat of substitutes - Impact of key factors in 2024 and 2029
7.6 Threat of rivalry
Threat of rivalry - Impact of key factors in 2024 and 2029
7.7 Market condition
Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Product
8.1 Market segments
Chart on Product - Market share 2024-2029 (%)
Data Table on Product - Market share 2024-2029 (%)
8.2 Comparison by Product
Chart on Comparison by Product
Data Table on Comparison by Product
8.3 Combination therapy - Market size and forecast 2024-2029
Chart on Combination therapy - Market size and forecast 2024-2029 ($ million)
Data Table on Combination therapy - Market size and forecast 2024-2029 ($ million)
Chart on Combination therapy - Year-over-year growth 2024-2029 (%)
Data Table on Combination therapy - Year-over-year growth 2024-2029 (%)
8.4 Monotherapy - Market size and forecast 2024-2029
Chart on Monotherapy - Market size and forecast 2024-2029 ($ million)
Data Table on Monotherapy - Market size and forecast 2024-2029 ($ million)
Chart on Monotherapy - Year-over-year growth 2024-2029 (%)
Data Table on Monotherapy - Year-over-year growth 2024-2029 (%)
8.5 Market opportunity by Product
Market opportunity by Product ($ million)
Data Table on Market opportunity by Product ($ million)
9 Market Segmentation by Distribution Channel
9.1 Market segments
Chart on Distribution Channel - Market share 2024-2029 (%)
Data Table on Distribution Channel - Market share 2024-2029 (%)
9.2 Comparison by Distribution Channel
Chart on Comparison by Distribution Channel
Data Table on Comparison by Distribution Channel
9.3 Hospital pharmacies - Market size and forecast 2024-2029
Chart on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
Data Table on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
Chart on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
Data Table on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
9.4 Retail pharmacies - Market size and forecast 2024-2029
Chart on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
Data Table on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
Chart on Retail pharmacies - Year-over-year growth 2024-2029 (%)
Data Table on Retail pharmacies - Year-over-year growth 2024-2029 (%)
9.5 Online pharmacies - Market size and forecast 2024-2029
Chart on Online pharmacies - Market size and forecast 2024-2029 ($ million)
Data Table on Online pharmacies - Market size and forecast 2024-2029 ($ million)
Chart on Online pharmacies - Year-over-year growth 2024-2029 (%)
Data Table on Online pharmacies - Year-over-year growth 2024-2029 (%)
9.6 Market opportunity by Distribution Channel
Market opportunity by Distribution Channel ($ million)
Data Table on Market opportunity by Distribution Channel ($ million)
10 Market Segmentation by Route of Administration
10.1 Market segments
Chart on Route of Administration - Market share 2024-2029 (%)
Data Table on Route of Administration - Market share 2024-2029 (%)
10.2 Comparison by Route of Administration
Chart on Comparison by Route of Administration
Data Table on Comparison by Route of Administration
10.3 Inhalation - Market size and forecast 2024-2029
Chart on Inhalation - Market size and forecast 2024-2029 ($ million)
Data Table on Inhalation - Market size and forecast 2024-2029 ($ million)
Chart on Inhalation - Year-over-year growth 2024-2029 (%)
Data Table on Inhalation - Year-over-year growth 2024-2029 (%)
10.4 Oral - Market size and forecast 2024-2029
Chart on Oral - Market size and forecast 2024-2029 ($ million)
Data Table on Oral - Market size and forecast 2024-2029 ($ million)
Chart on Oral - Year-over-year growth 2024-2029 (%)
Data Table on Oral - Year-over-year growth 2024-2029 (%)
10.5 Injectable - Market size and forecast 2024-2029
Chart on Injectable - Market size and forecast 2024-2029 ($ million)
Data Table on Injectable - Market size and forecast 2024-2029 ($ million)
Chart on Injectable - Year-over-year growth 2024-2029 (%)
Data Table on Injectable - Year-over-year growth 2024-2029 (%)
10.6 Market opportunity by Route of Administration
Market opportunity by Route of Administration ($ million)
Data Table on Market opportunity by Route of Administration ($ million)
11 Market Segmentation by Disease Type
11.1 Market segments
Chart on Disease Type - Market share 2024-2029 (%)
Data Table on Disease Type - Market share 2024-2029 (%)
11.2 Comparison by Disease Type
Chart on Comparison by Disease Type
Data Table on Comparison by Disease Type
11.3 Chronic bronchitis - Market size and forecast 2024-2029
Chart on Chronic bronchitis - Market size and forecast 2024-2029 ($ million)
Data Table on Chronic bronchitis - Market size and forecast 2024-2029 ($ million)
Chart on Chronic bronchitis - Year-over-year growth 2024-2029 (%)
Data Table on Chronic bronchitis - Year-over-year growth 2024-2029 (%)
11.4 Emphysema - Market size and forecast 2024-2029
Chart on Emphysema - Market size and forecast 2024-2029 ($ million)
Data Table on Emphysema - Market size and forecast 2024-2029 ($ million)
Chart on Emphysema - Year-over-year growth 2024-2029 (%)
Data Table on Emphysema - Year-over-year growth 2024-2029 (%)
11.5 Market opportunity by Disease Type
Market opportunity by Disease Type ($ million)
Data Table on Market opportunity by Disease Type ($ million)
12 Customer Landscape
12.1 Customer landscape overview
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
13 Geographic Landscape
13.1 Geographic segmentation
Chart on Market share By Geographical Landscape 2024-2029 (%)
Data Table on Market share By Geographical Landscape 2024-2029 (%)
13.2 Geographic comparison
Chart on Geographic comparison
Data Table on Geographic comparison
13.3 North America - Market size and forecast 2024-2029
Chart on North America - Market size and forecast 2024-2029 ($ million)
Data Table on North America - Market size and forecast 2024-2029 ($ million)
Chart on North America - Year-over-year growth 2024-2029 (%)
Data Table on North America - Year-over-year growth 2024-2029 (%)
13.4 Europe - Market size and forecast 2024-2029
Chart on Europe - Market size and forecast 2024-2029 ($ million)
Data Table on Europe - Market size and forecast 2024-2029 ($ million)
Chart on Europe - Year-over-year growth 2024-2029 (%)
Data Table on Europe - Year-over-year growth 2024-2029 (%)
13.5 Asia - Market size and forecast 2024-2029
Chart on Asia - Market size and forecast 2024-2029 ($ million)
Data Table on Asia - Market size and forecast 2024-2029 ($ million)
Chart on Asia - Year-over-year growth 2024-2029 (%)
Data Table on Asia - Year-over-year growth 2024-2029 (%)
13.6 Rest of World (ROW) - Market size and forecast 2024-2029
Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
13.7 US - Market size and forecast 2024-2029
Chart on US - Market size and forecast 2024-2029 ($ million)
Data Table on US - Market size and forecast 2024-2029 ($ million)
Chart on US - Year-over-year growth 2024-2029 (%)
Data Table on US - Year-over-year growth 2024-2029 (%)
13.8 Canada - Market size and forecast 2024-2029
Chart on Canada - Market size and forecast 2024-2029 ($ million)
Data Table on Canada - Market size and forecast 2024-2029 ($ million)
Chart on Canada - Year-over-year growth 2024-2029 (%)
Data Table on Canada - Year-over-year growth 2024-2029 (%)
13.9 Germany - Market size and forecast 2024-2029
Chart on Germany - Market size and forecast 2024-2029 ($ million)
Data Table on Germany - Market size and forecast 2024-2029 ($ million)
Chart on Germany - Year-over-year growth 2024-2029 (%)
Data Table on Germany - Year-over-year growth 2024-2029 (%)
13.10 China - Market size and forecast 2024-2029
Chart on China - Market size and forecast 2024-2029 ($ million)
Data Table on China - Market size and forecast 2024-2029 ($ million)
Chart on China - Year-over-year growth 2024-2029 (%)
Data Table on China - Year-over-year growth 2024-2029 (%)
13.11 France - Market size and forecast 2024-2029
Chart on France - Market size and forecast 2024-2029 ($ million)
Data Table on France - Market size and forecast 2024-2029 ($ million)
Chart on France - Year-over-year growth 2024-2029 (%)
Data Table on France - Year-over-year growth 2024-2029 (%)
13.12 UK - Market size and forecast 2024-2029
Chart on UK - Market size and forecast 2024-2029 ($ million)
Data Table on UK - Market size and forecast 2024-2029 ($ million)
Chart on UK - Year-over-year growth 2024-2029 (%)
Data Table on UK - Year-over-year growth 2024-2029 (%)
13.13 Japan - Market size and forecast 2024-2029
Chart on Japan - Market size and forecast 2024-2029 ($ million)
Data Table on Japan - Market size and forecast 2024-2029 ($ million)
Chart on Japan - Year-over-year growth 2024-2029 (%)
Data Table on Japan - Year-over-year growth 2024-2029 (%)
13.14 Spain - Market size and forecast 2024-2029
Chart on Spain - Market size and forecast 2024-2029 ($ million)
Data Table on Spain - Market size and forecast 2024-2029 ($ million)
Chart on Spain - Year-over-year growth 2024-2029 (%)
Data Table on Spain - Year-over-year growth 2024-2029 (%)
13.15 Brazil - Market size and forecast 2024-2029
Chart on Brazil - Market size and forecast 2024-2029 ($ million)
Data Table on Brazil - Market size and forecast 2024-2029 ($ million)
Chart on Brazil - Year-over-year growth 2024-2029 (%)
Data Table on Brazil - Year-over-year growth 2024-2029 (%)
13.16 The Netherlands - Market size and forecast 2024-2029
Chart on The Netherlands - Market size and forecast 2024-2029 ($ million)
Data Table on The Netherlands - Market size and forecast 2024-2029 ($ million)
Chart on The Netherlands - Year-over-year growth 2024-2029 (%)
Data Table on The Netherlands - Year-over-year growth 2024-2029 (%)
13.17 Market opportunity By Geographical Landscape
Market opportunity By Geographical Landscape ($ million)
Data Tables on Market opportunity By Geographical Landscape ($ million)
14 Drivers, Challenges, and Opportunity/Restraints
14.1 Market drivers
14.2 Market challenges
14.3 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
14.4 Market opportunities/restraints
15 Competitive Landscape
15.1 Overview
15.2 Competitive Landscape
Overview on criticality of inputs and factors of differentiation
15.3 Landscape disruption
Overview on factors of disruption
15.4 Industry risks
Impact of key risks on business
16 Competitive Analysis
16.1 Companies profiled
16.2 Company ranking index
16.3 Market positioning of companies
Matrix on companies position and classification
16.4 AstraZeneca Plc
AstraZeneca Plc - Overview
AstraZeneca Plc - Product / Service
AstraZeneca Plc - Key news
AstraZeneca Plc - Key offerings
SWOT
16.5 Boehringer Ingelheim International GmbH
Boehringer Ingelheim International GmbH - Overview
Boehringer Ingelheim International GmbH - Product / Service
Boehringer Ingelheim International GmbH - Key news
Boehringer Ingelheim International GmbH - Key offerings
SWOT
16.6 Cadila Pharmaceuticals Ltd.
Cadila Pharmaceuticals Ltd. - Overview
Cadila Pharmaceuticals Ltd. - Product / Service
Cadila Pharmaceuticals Ltd. - Key offerings
SWOT
16.7 Cipla Inc.
Cipla Inc. - Overview
Cipla Inc. - Business segments
Cipla Inc. - Key news
Cipla Inc. - Key offerings
Cipla Inc. - Segment focus
SWOT
16.8 GlaxoSmithKline Plc
GlaxoSmithKline Plc - Overview
GlaxoSmithKline Plc - Business segments
GlaxoSmithKline Plc - Key news
GlaxoSmithKline Plc - Key offerings
GlaxoSmithKline Plc - Segment focus
SWOT
16.9 Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd. - Overview
Glenmark Pharmaceuticals Ltd. - Product / Service
Glenmark Pharmaceuticals Ltd. - Key offerings
SWOT
16.10 Innoviva Inc.
Innoviva Inc. - Overview
Innoviva Inc. - Product / Service
Innoviva Inc. - Key news
Innoviva Inc. - Key offerings
SWOT
16.11 Lupin Ltd.
Lupin Ltd. - Overview
Lupin Ltd. - Business segments
Lupin Ltd. - Key news
Lupin Ltd. - Key offerings
Lupin Ltd. - Segment focus
SWOT
16.12 Merck and Co. Inc.
Merck and Co. Inc. - Overview
Merck and Co. Inc. - Business segments
Merck and Co. Inc. - Key news
Merck and Co. Inc. - Key offerings
Merck and Co. Inc. - Segment focus
SWOT
16.13 Novartis AG
Novartis AG - Overview
Novartis AG - Business segments
Novartis AG - Key news
Novartis AG - Key offerings
Novartis AG - Segment focus
SWOT
16.14 SHIONOGI Co. Ltd.
SHIONOGI Co. Ltd. - Overview
SHIONOGI Co. Ltd. - Product / Service
SHIONOGI Co. Ltd. - Key offerings
SWOT
16.15 Sumitomo Pharma Co. Ltd.
Sumitomo Pharma Co. Ltd. - Overview
Sumitomo Pharma Co. Ltd. - Business segments
Sumitomo Pharma Co. Ltd. - Key offerings
Sumitomo Pharma Co. Ltd. - Segment focus
SWOT
16.16 Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. - Overview
Teva Pharmaceutical Industries Ltd. - Business segments
Teva Pharmaceutical Industries Ltd. - Key news
Teva Pharmaceutical Industries Ltd. - Key offerings
Teva Pharmaceutical Industries Ltd. - Segment focus
SWOT
16.17 Theravance Biopharma Inc.
Theravance Biopharma Inc. - Overview
Theravance Biopharma Inc. - Product / Service
Theravance Biopharma Inc. - Key offerings
SWOT
16.18 Viatris Inc.
Viatris Inc. - Overview
Viatris Inc. - Business segments
Viatris Inc. - Key news
Viatris Inc. - Key offerings
Viatris Inc. - Segment focus
SWOT
17 Appendix
17.1 Scope of the report
17.2 Inclusions and exclusions checklist
Inclusions checklist
Exclusions checklist
17.3 Currency conversion rates for US$
Currency conversion rates for US$
17.4 Research methodology
17.5 Data procurement
17.6 Data validation
17.7 Validation techniques employed for market sizing
Validation techniques employed for market sizing
17.8 Data synthesis
17.9 360 degree market analysis
360 degree market analysis
17.10 List of abbreviations